A U.S. Patent for “Primary Cell Gene Editing” was awarded to PACT Pharmaon February 4th, 2020. The present invention is a method of treating a cancer in a human patient comprising: a. modifying a patient-derived T cell by a nuclease-mediated introduction of a non-viral polynucleotide into the T cell, wherein the non-viral polynucleotide comprises: i. first and second homology arms homologous to first and second endogenous sequences of the cell; ii. a TCR gene sequence positioned between the first and second homology arms; iii. a first P2A-coding sequence positioned upstream of the TCR gene sequence… Learn More